Despite these setbacks, Pfizer appears committed to the obesity market and continues to progress PF-07976016, a first-in-class, orally delivered small molecule GIP receptor antagonist for treatment of obesity, for which safety and efficacy is currently being evaluated in a dose-ranging Phase II study, (NCT06717425)
The 500mcg oral dose in this formula is substantially lower than the doses used in pre-clinical injectable research
Approved Health Claims for Vitamin B12 (EFSA): Vitamin B12 contributes to: Normal energy-yielding metabolism Normal functioning of the nervous system Normal homocysteine metabolism Normal psychological function Normal red blood cell formation Normal function of the immune system The reduction of tiredness and fatigue The role in the process of cell division Food supplements should not be used as a substitute for a varied diet
For anyone building a peptide stack for weight loss or comparing options, this magnitude of difference is unprecedented in the history of obesity pharmacotherapy
Finasteride's pivotal trial, a two-year randomized placebo-controlled study of 1,553 men with androgenetic alopecia, found that 83 percent of finasteride users maintained or increased their hair count compared to 28 percent in the placebo group [5]